Wang H, Li W. Recent update on comprehensive therapy for advanced hepatocellular carcinoma. World J Gastrointest Oncol 2021; 13(8): 845-855 [PMID: 34457190 DOI: 10.4251/wjgo.v13.i8.845]
Corresponding Author of This Article
Wei Li, MD, PhD, Professor, Department of Hepatobiliary-Pancreatic Surgery, China-Japan Union Hospital of Jilin University, No. 126 Xiantai Street, Changchun 130033, Jilin Province, China. weili888@jlu.edu.cn
Research Domain of This Article
Oncology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Aug 15, 2021; 13(8): 845-855 Published online Aug 15, 2021. doi: 10.4251/wjgo.v13.i8.845
Recent update on comprehensive therapy for advanced hepatocellular carcinoma
Hui Wang, Wei Li
Hui Wang, Wei Li, Department of Hepatobiliary-Pancreatic Surgery, China-Japan Union Hospital of Jilin University, Changchun 130033, Jilin Province, China
Author contributions: Wang H initially collected and organized the literature and drafted the manuscript; Li W contributed to the conceptual design and carried out critical revision and finalization of the manuscript.
Supported byNature Science Foundation of the Science and Technology Bureau of Jilin Province, No. 20190201227JC; and Innovation Capacity-building Fund of the Development and Reform Commission of Jilin Province, No. 2019C015.
Conflict-of-interest statement: The authors have no conflict of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wei Li, MD, PhD, Professor, Department of Hepatobiliary-Pancreatic Surgery, China-Japan Union Hospital of Jilin University, No. 126 Xiantai Street, Changchun 130033, Jilin Province, China. weili888@jlu.edu.cn
Received: February 18, 2021 Peer-review started: February 19, 2021 First decision: March 29, 2021 Revised: April 12, 2021 Accepted: June 23, 2021 Article in press: June 23, 2021 Published online: August 15, 2021 Processing time: 177 Days and 0.3 Hours
Abstract
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world. The treatment methods for HCC are diverse, mainly including surgical resection, ablation, and liver transplantation. The curative effect can be achieved only for early stage HCC, and it is easy to recur and metastasize after surgery, with a 5-year recurrence rate as high as 70%. Most patients with HCC are in the middle and advanced stage at the time of diagnosis and lose the chance of surgical resection. In recent years, with the in-depth study of the pathogenesis of HCC and the progress of medical science and technology, the systemic treatment of advanced HCC has made a breakthrough. At present, multidisciplinary comprehensive treatment including targeted therapy and immunotherapy has become an effective strategy and inevitable trend for the treatment of advanced HCC. Combined therapy has greatly improved the prognosis of HCC patients and opened up a new milestone in the treatment of this malignancy. In this article, we focus on the treatment progress of advanced HCC to further guide clinical practice.
Core Tip: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world. The curative effect can be achieved only for early stage HCC, and it is easy to recur and metastasize after surgery, with a 5-year recurrence rate as high as 70%. Recently, the systematic treatment of advanced HCC has made a breakthrough. Multidisciplinary comprehensive treatment including targeted therapy and immunotherapy has become an effective strategy and inevitable trend for the treatment of advanced HCC. Combined therapy has greatly improved the prognosis of HCC patients and opened up a new milestone in the treatment of this malignancy.
